lundi 24 août 2026
RechercherExplore
fr.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 9, 2026

Precision Medicine Analysis Report 2026: A $237.28 Billion Market by 2031 - Strategic Pharma-Big-Tech Alliances Speeding Precision Drug Discovery

View original at globenewswire.com
Precision Medicine Analysis Report 2026: A $237.28 Billion Market by 2031 - Strategic Pharma-Big-Tech Alliances Speeding Precision Drug Discovery Dublin, Feb…
Opening lines of the source · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Asia-Pacific is the fastest-growing region with a 14.12% CAGR

    80% confidence

  • More than 15 FDA clearances since 2024 have tied targeted drugs to specific biomarker tests, widening the addressable patient pool for precision oncology

    80% confidence

  • Next-generation sequencing captured 33.78% of the precision medicine market share in 2025

    80% confidence

  • Guardant Health's Shield blood test detects colorectal cancer with 83% sensitivity in average-risk adults

    80% confidence

  • North America led the precision medicine market with a 47.85% revenue share in 2025

    80% confidence

  • SomaLogic measures 10,000 proteins from a microliter sample, producing high-density data that AI models translate into early disease risk scores

    80% confidence

  • The Precision Medicine market size in 2026 is estimated at USD 125.71 billion, growing from 2025 value of USD 110.68 billion with 2031 projections showing USD 237.28 billion, growing at 13.58% CAGR over 2026-2031

    80% confidence

  • China's Human Genome Project 2 plans to sequence 80 million genomes, creating the world's largest reference panel for variant interpretation

    80% confidence

  • Artificial intelligence and machine learning is the fastest-growing segment at a 17.62% CAGR

    80% confidence

  • Japan has committed to analyze 100,000 cancer genomes under a national program to guide targeted therapy development

    80% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Notre lecture des données ›
Signaux que nous suivons
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Tendances que nous surveillons ›
Là où les sources divergent
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,978
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,978 faits vérifiés avec la source5,251 documents sources archivés
Interrogez ces données → isubstrate.com